DaVita Inc. (NYSE:DVA) Holdings Cut by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp lessened its stake in DaVita Inc. (NYSE:DVA - Free Report) by 32.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,287 shares of the company's stock after selling 5,327 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in DaVita were worth $1,688,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in DVA. NDVR Inc. increased its stake in DaVita by 28.9% during the fourth quarter. NDVR Inc. now owns 1,714 shares of the company's stock worth $256,000 after acquiring an additional 384 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new position in DaVita during the fourth quarter valued at approximately $1,645,000. Iron Triangle Partners LP purchased a new stake in DaVita during the fourth quarter worth approximately $38,946,000. Jefferies Financial Group Inc. increased its position in shares of DaVita by 28.6% in the fourth quarter. Jefferies Financial Group Inc. now owns 174,880 shares of the company's stock worth $26,153,000 after acquiring an additional 38,855 shares in the last quarter. Finally, Gotham Asset Management LLC raised its stake in shares of DaVita by 53.6% in the 4th quarter. Gotham Asset Management LLC now owns 131,345 shares of the company's stock valued at $19,643,000 after acquiring an additional 45,859 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Down 0.4%

DVA stock traded down $0.58 during midday trading on Monday, hitting $144.83. 940,279 shares of the company's stock were exchanged, compared to its average volume of 830,820. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The firm has a 50 day moving average price of $145.68 and a 200-day moving average price of $153.57. The stock has a market capitalization of $10.93 billion, a price-to-earnings ratio of 13.49, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. DaVita Inc. has a 12-month low of $131.44 and a 12-month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.26 earnings per share. On average, analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DVA. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Truist Financial lowered their target price on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. Finally, Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, DaVita presently has a consensus rating of "Hold" and an average price target of $164.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.